River Street Advisors LLC Purchases 41 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

River Street Advisors LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.0% during the fourth quarter, Holdings Channel reports. The firm owned 553 shares of the biopharmaceutical company’s stock after buying an additional 41 shares during the quarter. River Street Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $394,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. International Assets Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $127,489,000. KBC Group NV lifted its holdings in Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after purchasing an additional 102,198 shares during the last quarter. Icon Wealth Advisors LLC boosted its position in Regeneron Pharmaceuticals by 18,342.0% during the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock worth $79,874,000 after purchasing an additional 75,569 shares during the period. Finally, State Street Corp increased its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $672.98 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The stock has a market capitalization of $73.95 billion, a P/E ratio of 16.65, a price-to-earnings-growth ratio of 1.62 and a beta of 0.10. The stock has a fifty day moving average of $720.81 and a 200-day moving average of $922.87.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Sanford C. Bernstein cut their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,004.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.